Table 1.
Overall and Item-Specific Change in Knowledge from Pre- to Post-Test ENRICH Course Participation (n=77)
| Item Content | Correct (pre-test) |
Correct (post- test) |
P value |
|---|---|---|---|
| Overall Knowledge (% of total items correct) | 58% | 77% | <0.001 |
| Fertility Risks | |||
| Fertility risk in young male oncology patient previously treated with prednisone for rheumatoid arthritis. | 57% | 73% | 0.05 |
| Impact of cancer site on sperm count and sperm motility. | 78% | 93% | <0.01 |
| Impact of age, gender, and radiation site on future fertility outcomes. | 24% | 33% | 0.30 |
| Impact of chemotherapeutic agents on gonadal damage and fertility. | 64% | 91% | <0.001 |
| Impact of age, gender, and cancer site on fertility. | 77% | 93% | 0.04 |
| FP Options | |||
| Standard methods to obtain sperm from men prior to treatment. | 73% | 86% | 0.04 |
| Success rates for female FP methods. | 67% | 85% | <0.01 |
| Pregnancy success rates with embryos cryopreserved prior to receiving chemotherapy with alkylating | 40% | 59% | 0.07 |
| Benefits and limitations of oophoropexy. | 54% | 79% | <0.001 |
| Success rates for male FP options. | 41% | 62% | <0.01 |
| Use of Tanner Stage to determine FP options. | 49% | 85% | <0.001 |
| Sexual Function | |||
| Impact of nerve-sparing radical prostatectomy on sexual function. | 72% | 69% | 0.83 |
| Impact of biologic response modifiers on sexual function. | 54% | 83% | <0.001 |
| Physical effects of targeted therapies on sexual function. | 61% | 85% | <0.01 |